147 related articles for article (PubMed ID: 35792806)
1. Can we use Ki67 expression to predict prostate cancer aggressiveness?
Maia R; Santos GAD; Reis S; Viana NI; Pimenta R; Guimarães VR; Recuero S; Romão P; Leite KRM; Srougi M; Passerotti CC
Rev Col Bras Cir; 2022; 49():e20223200. PubMed ID: 35792806
[TBL] [Abstract][Full Text] [Related]
2. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
[TBL] [Abstract][Full Text] [Related]
3. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
Lobo J; Rodrigues Â; Antunes L; Graça I; Ramalho-Carvalho J; Vieira FQ; Martins AT; Oliveira J; Jerónimo C; Henrique R
Urol Oncol; 2018 Apr; 36(4):161.e7-161.e17. PubMed ID: 29174711
[TBL] [Abstract][Full Text] [Related]
4. KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer-a targeted molecular approach.
Green WJ; Ball G; Hulman G; Johnson C; Van Schalwyk G; Ratan HL; Soria D; Garibaldi JM; Parkinson R; Hulman J; Rees R; Powe DG
Br J Cancer; 2016 Jul; 115(2):236-42. PubMed ID: 27336609
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies.
Tretiakova MS; Wei W; Boyer HD; Newcomb LF; Hawley S; Auman H; Vakar-Lopez F; McKenney JK; Fazli L; Simko J; Troyer DA; Hurtado-Coll A; Thompson IM; Carroll PR; Ellis WJ; Gleave ME; Nelson PS; Lin DW; True LD; Feng Z; Brooks JD
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):264-70. PubMed ID: 27136741
[TBL] [Abstract][Full Text] [Related]
6. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer.
Bubendorf L; Tapia C; Gasser TC; Casella R; Grunder B; Moch H; Mihatsch MJ; Sauter G
Hum Pathol; 1998 Sep; 29(9):949-54. PubMed ID: 9744310
[TBL] [Abstract][Full Text] [Related]
7. Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome.
Hammarsten P; Josefsson A; Thysell E; Lundholm M; Hägglöf C; Iglesias-Gato D; Flores-Morales A; Stattin P; Egevad L; Granfors T; Wikström P; Bergh A
Mod Pathol; 2019 Sep; 32(9):1310-1319. PubMed ID: 30980038
[TBL] [Abstract][Full Text] [Related]
8. Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study.
Fantony JJ; Howard LE; Csizmadi I; Armstrong AJ; Lark AL; Galet C; Aronson WJ; Freedland SJ
Biomark Med; 2018 Jul; 12(7):727-736. PubMed ID: 29902938
[TBL] [Abstract][Full Text] [Related]
9. Prolactin- and testosterone-induced carboxypeptidase-D correlates with increased nitrotyrosines and Ki67 in prostate cancer.
Thomas LN; Merrimen J; Bell DG; Rendon R; Too CK
Prostate; 2015 Nov; 75(15):1726-36. PubMed ID: 26202060
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort.
Richardsen E; Andersen S; Al-Saad S; Rakaee M; Nordby Y; Pedersen MI; Ness N; Grindstad T; Movik I; Dønnem T; Bremnes R; Busund LT
PLoS One; 2017; 12(11):e0186852. PubMed ID: 29141018
[TBL] [Abstract][Full Text] [Related]
11. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy.
Cowen D; Troncoso P; Khoo VS; Zagars GK; von Eschenbach AC; Meistrich ML; Pollack A
Clin Cancer Res; 2002 May; 8(5):1148-54. PubMed ID: 12006531
[TBL] [Abstract][Full Text] [Related]
12. COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-beta, IL-10 and Ki67.
Richardsen E; Uglehus RD; Due J; Busch C; Busund LT
Cancer Epidemiol; 2010 Jun; 34(3):316-22. PubMed ID: 20409773
[TBL] [Abstract][Full Text] [Related]
13. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.
Pollack A; DeSilvio M; Khor LY; Li R; Al-Saleem TI; Hammond ME; Venkatesan V; Lawton CA; Roach M; Shipley WU; Hanks GE; Sandler HM
J Clin Oncol; 2004 Jun; 22(11):2133-40. PubMed ID: 15169799
[TBL] [Abstract][Full Text] [Related]
14. Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08.
Verhoven B; Yan Y; Ritter M; Khor LY; Hammond E; Jones C; Amin M; Bahary JP; Zeitzer K; Pollack A
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):317-23. PubMed ID: 23474109
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of minichromosome maintenance complex protein 2 predicts biochemical recurrence in prostate cancer: a tissue microarray and digital imaging analysis-based study of 428 cases.
Toubaji A; Sutcliffe S; Chaux A; Lecksell K; Hicks J; De Marzo AM; Platz EA; Netto GJ
Hum Pathol; 2012 Nov; 43(11):1852-65. PubMed ID: 22554381
[TBL] [Abstract][Full Text] [Related]
16. A tissue miRNA expression pattern is associated with disease aggressiveness of localized prostate cancer.
Juracek J; Madrzyk M; Stanik M; Ruckova M; Trachtova K; Malcikova H; Lzicarova E; Barth DA; Pichler M; Slaby O
Prostate; 2023 Mar; 83(4):340-351. PubMed ID: 36478451
[TBL] [Abstract][Full Text] [Related]
17. [The usefulness of Ki67 expression in the biopsy specimens, to predict the biochemical progresion of the prostate cancer after radical prostatectomy].
Ojea Calvo A; Mosteiro Cerviño MJ; Domínguez Freire F; Alonso Rodrigo A; Rodríguez Iglesias B; Benavente Delgado J; Barros Rodríguez JM; González Piñeiro A
Actas Urol Esp; 2004 Oct; 28(9):650-60. PubMed ID: 16050199
[TBL] [Abstract][Full Text] [Related]
18. Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.
Lindsay CR; Le Moulec S; Billiot F; Loriot Y; Ngo-Camus M; Vielh P; Fizazi K; Massard C; Farace F
BMC Cancer; 2016 Feb; 16():168. PubMed ID: 26923772
[TBL] [Abstract][Full Text] [Related]
19. Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance.
Josefsson A; Wikström P; Egevad L; Granfors T; Karlberg L; Stattin P; Bergh A
Scand J Urol Nephrol; 2012 Aug; 46(4):247-57. PubMed ID: 22452635
[TBL] [Abstract][Full Text] [Related]
20. Role of co-expression of estrogen receptor beta and Ki67 in prostate adenocarcinoma.
Azizan N; Hayati F; Tizen NMS; Farouk WI; Masir N
Investig Clin Urol; 2018 Jul; 59(4):232-237. PubMed ID: 29984337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
